AUTL: רווח נקי למניה (EPS TTM) Autolus Pharma

Risks for Autolus Therapeutics (AUTL) are linked to biomaterial logistics and product scaling rates, as evidenced by the trailing 12-month earnings per share, where the value of -0.96 serves as the current metric. Stability is ensured by The Nucleus, the company's own manufacturing facility in Britain. The strategy is based on creating programmable T-cells for leukemia treatment and reducing costs through production automation.

This metric measures actual business efficiency by dividing total annual net income by the total number of shares to evaluate the earnings per share. Analyzing the rolling 12-month EPS allows for tracking the impact of CAR-T therapy manufacturing complexities and insurance reimbursement challenges on the bottom-line profitability of Autolus Therapeutics (AUTL), signaling the company's ability to generate value amidst fierce competition.